Relay Therapeutics Inc (NASDAQ: RLAY) kicked off on Monday, down -4.46% from the previous trading day, before settling in for the closing price of $6.73. Over the past 52 weeks, RLAY has traded in a range of $5.70-$12.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 319.82% over the past five years. While this was happening, its average annual earnings per share was recorded -2.18%. With a float of $120.66 million, this company’s outstanding shares have now reached $127.46 million.
Let’s look at the performance matrix of the company that is accounted for 323 employees. In terms of profitability, gross margin is 84.38%, operating margin of -1051.18%, and the pretax margin is -916.92%.
Relay Therapeutics Inc (RLAY) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 25.73%, while institutional ownership is 55.84%. The most recent insider transaction that took place on Sep 27 ’24, was worth 1,840. In this transaction an insider of this company sold 245 shares at a rate of $7.51, taking the stock ownership to the 391,684 shares. Before that another transaction happened on Sep 27 ’24, when Company’s Chief Financial Officer sold 6,457 for $7.46, making the entire transaction worth $48,184. This insider now owns 313,193 shares in total.
Relay Therapeutics Inc (RLAY) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.54 earnings per share (EPS), higher than consensus estimate (set at -0.83) by 0.29. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.74 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.18% per share during the next fiscal year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Take a look at Relay Therapeutics Inc’s (RLAY) current performance indicators. Last quarter, stock had a quick ratio of 15.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.52, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -3.14 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Relay Therapeutics Inc (NASDAQ: RLAY) saw its 5-day average volume 1.12 million, a negative change from its year-to-date volume of 1.46 million. As of the previous 9 days, the stock’s Stochastic %D was 58.77%. Additionally, its Average True Range was 0.46.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 10.44%, which indicates a significant decrease from 43.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.31% in the past 14 days, which was lower than the 95.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.03, while its 200-day Moving Average is $7.84. Nevertheless, the first resistance level for the watch stands at $6.66 in the near term. At $6.89, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.01. If the price goes on to break the first support level at $6.31, it is likely to go to the next support level at $6.19. The third support level lies at $5.96 if the price breaches the second support level.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
The company with the Market Capitalisation of 1.04 billion has total of 132,742K Shares Outstanding. Its annual sales at the moment are 25,550 K in contrast with the sum of -341,970 K annual income. Company’s last quarter sales were recorded 10,010 K and last quarter income was -81,390 K.
